Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 157,305,424
  • Shares Outstanding, K 5,662,542
  • Annual Sales, $ 58,496 M
  • Annual Income, $ 2,119 M
  • 60-Month Beta 0.61
  • Price/Sales 2.67
  • Price/Cash Flow 9.22
  • Price/Book 1.73
Trade PFE with:

Options Overview Details

View History
  • Implied Volatility 23.75% ( +0.10%)
  • Historical Volatility 23.30%
  • IV Percentile 40%
  • IV Rank 34.70%
  • IV High 33.73% on 10/27/23
  • IV Low 18.44% on 06/09/23
  • Put/Call Vol Ratio 0.39
  • Today's Volume 214,775
  • Volume Avg (30-Day) 190,211
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 2,797,923
  • Open Int (30-Day) 2,799,614

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.57
  • Number of Estimates 8
  • High Estimate 0.82
  • Low Estimate 0.49
  • Prior Year 1.23
  • Growth Rate Est. (year over year) -53.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.61 +8.36%
on 03/04/24
28.69 -3.28%
on 03/13/24
+0.71 (+2.63%)
since 02/28/24
3-Month
25.61 +8.36%
on 03/04/24
30.28 -8.35%
on 01/02/24
-1.04 (-3.61%)
since 12/28/23
52-Week
25.61 +8.36%
on 03/04/24
42.22 -34.27%
on 04/05/23
-12.24 (-30.61%)
since 03/28/23

Most Recent Stories

More News
3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000

Each of these three companies are entering a new era of growth.

PFE : 27.75 (-0.11%)
CRSP : 68.16 (-2.85%)
MDT : 87.15 (+0.26%)
SEC Explores New Territory in Insider Trading Case Against Ex-Biotech Exec

In a groundbreaking trial in San Francisco, the U.S. Securities and Exchange Commission (SEC) is testing the boundaries of insider trading laws. The case against former biotech executive Matthew Panuwat...

PFE : 27.75 (-0.11%)
INCY : 56.97 (-0.26%)
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold Forever

If you have a Benjamin burning a hole in your pocket, these stocks are a great way to invest it.

MO : 43.62 (-0.09%)
PFE : 27.75 (-0.11%)
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition

Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants.

NVO : 128.40 (+0.27%)
LLY : 777.96 (-0.03%)
VKTX : 82.00 (-1.61%)
PFE : 27.75 (-0.11%)
3 Ultra-High-Yield Dividend Stocks That Could Realistically Double Your Money by 2030

There's no guarantee these stocks can generate 100% returns by 2030. But they have a clear path to make it happen.

ARCC : 20.82 (+1.66%)
EPD : 29.18 (+0.45%)
PFE : 27.75 (-0.11%)
Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?

What's good for Wood and Ark Invest might not be good for other investors.

ARKG : 28.76 (+0.74%)
PFE : 27.75 (-0.11%)
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

The price could be right for these three biopharma stocks.

AXSM : 79.80 (+0.80%)
CRSP : 68.16 (-2.85%)
PFE : 27.75 (-0.11%)
A Bull Market Is Here: 2 Magnificent Stocks Down 30% or More to Buy Right Now

These stocks share several things in common.

PFE : 27.75 (-0.11%)
MRNA : 106.56 (-3.64%)
2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?

After a lousy year of declining prices, these stocks offer yields of 4.7% and 6.1% at recent prices.

PFE : 27.75 (-0.11%)
WBA : 21.69 (+3.19%)
Will Pfizer Be a Trillion-Dollar Stock by 2035?

A market cap of $1 trillion for Pfizer over the next 11 or so years? Possible, but not probable.

PFE : 27.75 (-0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 28.41
2nd Resistance Point 28.26
1st Resistance Point 28.01
Last Price 27.75
1st Support Level 27.61
2nd Support Level 27.46
3rd Support Level 27.21

See More

52-Week High 42.22
Fibonacci 61.8% 35.87
Fibonacci 50% 33.92
Fibonacci 38.2% 31.96
Last Price 27.75
52-Week Low 25.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar